Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | SCLC hyperprogression with nivolumab

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses an analysis of tumor hyperprogression (HP) with nivolumab in small- cell lung cancer (SCLC) randomized, placebo-controlled trials. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.